Newron Pharmaceuticals S.p.A. (0QOI.L)
CHF 8.22
(0.24%)
CHF 8.22
(0.24%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.14 Million | -11.09 Million | -11.44 Million | -15.58 Million | -21.97 Million | -15.95 Million |
| Net Income | -16.2 Million | -17.49 Million | -14.9 Million | -20.99 Million | -20.2 Million | -15.03 Million |
| Depreciation & Amortization | 201 Thousand | 202 Thousand | 209 Thousand | 219 Thousand | 206 Thousand | 192 Thousand |
| Deferred income taxes | - | 402 Thousand | -2.51 Million | -2.68 Million | -1.96 Million | -5.1 Million |
| Stock-based compensation | 197 Thousand | 480 Thousand | 762 Thousand | 1.46 Million | 2.12 Million | 2.1 Million |
| Change in working capital | 1.63 Million | -882 Thousand | 1.75 Million | 1.22 Million | -158 Thousand | 2.99 Million |
| Other non-cash items | 4.02 Million | 6.19 Million | 3.24 Million | 5.19 Million | -1.97 Million | -1.11 Million |
| Investing Cash Flow | 3.24 Million | -317 Thousand | 8.42 Million | -616 Thousand | -932 Thousand | 2.96 Million |
| Investments in PPE | -11 Thousand | -18 Thousand | -20 Thousand | -34 Thousand | -51 Thousand | -34 Thousand |
| Acquisitions | -3.25 Million | 299 Thousand | -8.44 Million | 581 Thousand | 881 Thousand | - |
| Investment purchases | -981 Thousand | -3.04 Million | -1.69 Million | -2.21 Million | -3.05 Million | - |
| Sales/Maturities of investments | 4.23 Million | 2.74 Million | 10.13 Million | 1.63 Million | 2.17 Million | 3 Million |
| Other Investing Activities | 3.25 Million | -299 Thousand | 8.44 Million | -582 Thousand | -881 Thousand | -6000.00 |
| Financing Cash Flow | -192 Thousand | -186 Thousand | 14.83 Million | 7.36 Million | 17.33 Million | -27 Thousand |
| Debt repayment | -192 Thousand | -186 Thousand | -169 Thousand | -135 Thousand | -163 Thousand | -154 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | 51 Thousand |
| Other Financing Activities | -192 Thousand | -186 Thousand | 15 Million | 7.5 Million | 17.5 Million | 76 Thousand |
| Accounts receivables | -1.3 Million | -882 Thousand | 1.75 Million | 1.22 Million | -158 Thousand | 2.99 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | 5000.00 |
| Other working capital | 2.94 Million | 2.19 Million | 1.93 Million | 1.93 Million | -12 Thousand | -2000.00 |
| Cash at beginning of period | 13.42 Million | 25.01 Million | 13.21 Million | 22.05 Million | 27.62 Million | 40.64 Million |
| Cash at end of period | 6.33 Million | 13.42 Million | 25.01 Million | 13.21 Million | 22.05 Million | 27.62 Million |
| Capital Expenditure | -11 Thousand | -18 Thousand | -20 Thousand | -34 Thousand | -51 Thousand | -34 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -7.08 Million | -11.59 Million | 11.8 Million | -8.83 Million | -5.57 Million | -13.01 Million |
| Free Cash Flow | -10.15 Million | -11.11 Million | -11.46 Million | -15.62 Million | -22.02 Million | -15.98 Million |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -9.55 Million | -16.2 Million | -9.27 Million | -6.95 Million | -17.49 Million | -8.85 Million |
| Depreciation & Amortization | 96 Thousand | 201 Thousand | 99 Thousand | 102 Thousand | 202 Thousand | 103 Thousand |
| Deferred income taxes | - | - | - | 1.36 Million | 402 Thousand | 137 Thousand |
| Stock-based compensation | 170 Thousand | 197 Thousand | 142 Thousand | 55 Thousand | 480 Thousand | 130 Thousand |
| Change in working capital | 468 Thousand | 1.63 Million | 958 Thousand | -22 Thousand | -882 Thousand | 673 Thousand |
| Other non-cash items | -5000.00 | 4.02 Million | 3.53 Million | 1.21 Million | 6.19 Million | 2.48 Million |
| Investing Cash Flow | 2 Million | 3.24 Million | 3.25 Million | -11 Thousand | -317 Thousand | 97 Thousand |
| Investments in PPE | -7000.00 | -11 Thousand | -3000.00 | -8000.00 | -18 Thousand | -9000.00 |
| Acquisitions | - | -3.25 Million | - | - | 299 Thousand | - |
| Investment purchases | - | -981 Thousand | - | - | -3.04 Million | - |
| Sales/Maturities of investments | - | 4.23 Million | - | - | 2.74 Million | - |
| Other Investing Activities | 2.01 Million | 3.25 Million | 3.26 Million | -3000.00 | -299 Thousand | 106 Thousand |
| Financing Cash Flow | 8.37 Million | -192 Thousand | -95 Thousand | -97 Thousand | -186 Thousand | -94 Thousand |
| Debt repayment | -97 Thousand | -192 Thousand | - | -97 Thousand | -186 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 8.47 Million | - | -95 Thousand | -97 Thousand | -186 Thousand | -94 Thousand |
| Accounts receivables | -826 Thousand | -1.3 Million | 109 Thousand | -1.41 Million | -882 Thousand | -267 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.29 Million | 2.94 Million | 849 Thousand | 1.39 Million | 2.19 Million | 940 Thousand |
| Cash at beginning of period | 6.33 Million | 13.42 Million | 7.71 Million | - | 25.01 Million | 18.88 Million |
| Cash at end of period | 7.89 Million | 6.33 Million | - | 7.71 Million | 13.42 Million | - |
| Capital Expenditure | -7000.00 | -11 Thousand | -3000.00 | -8000.00 | -18 Thousand | -9000.00 |
| Effect of forex changes on cash | - | - | -6.33 Million | 13.42 Million | - | -13.42 Million |
| Net cash flow / Change in cash | 1.55 Million | -7.08 Million | -7.71 Million | 7.71 Million | -11.59 Million | -18.88 Million |
| Free Cash Flow | -8.83 Million | -10.15 Million | -4.54 Million | -5.61 Million | -11.11 Million | -5.47 Million |
HMI
CIFR
3778
1856
TEXELIN
PMOIF